Plus Therapeutics, Inc. announced on February 24, 2025, key leadership appointments for its wholly-owned subsidiary, CNSide Diagnostics, LLC. Mr. Russell Bradley was named President and General Manager of CNSide Diagnostics.
Mr. Bradley brings over 30 years of leadership experience in diagnostics and life sciences, having held senior executive roles at Abbott Laboratories, Luminex Corporation, and Beckman Coulter. His expertise is expected to make an immediate impact as CNSide prepares for a pilot market introduction.
Additionally, Dr. Marc Hedrick, Mr. Rick Hawkins, and Mr. Russell Bradley were appointed to the CNSide Board of Directors, and Dr. Jonathan Stein was named CNSide Medical Director. These appointments aim to capitalize CNSide Diagnostics to support its early access and initial launch plans in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.